Indications
Aximin is indicated in-
- Treatment of traveler's diarrhea caused by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome.
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. Very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. Rifaximin inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. It shows the same broad spectrum activity as rifamycin which exerts bactericidal action against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- Travelers' Diarrhea: Rifaximin is indicated for the treatment of traveler's diarrhea.
- Hepatic Encephalopathy: Rifaximin is indicated for the reduction in risk of overt hepatic encephalopathy.
- Irritable Bowel Syndrome with Diarrhea: Rifaximin is indicated for irritable bowel syndrome with diarrhea.
Interaction
An in vitro study has suggested that Aximin induces CYP3A4. However, in patients with normal liver function, Aximin at standard regimens is not expected to induce CYP3A4.
Contraindications
Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product.
Side Effects
Side effects include flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, constipation, pyrexia, and vomiting. Hypersensitivity reactions have been reported, including anaphylaxis, angioneurotic edema, and exfoliative dermatitis.
Pregnancy & Lactation
Pregnancy category C. It is not known whether Rifaximin is excreted in human milk or not.
Precautions & Warnings
Aximin is not found to be effective in patients with diarrhea complicated by fever and/or blood in the stools. Aximin therapy should be discontinued if diarrhea symptoms get worse or persist for more than 24-48 hours and alternative antibiotic therapy should be considered. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.
Use in Special Populations
- Renal Impairment: The pharmacokinetics of Aximin in patients with impaired renal function has not been studied.
- Hepatic Impairment: The systemic exposure of Aximin was markedly elevated in patients with hepatic impairment compared to healthy subjects.
Overdose Effects
No specific information is available on the treatment of overdosage with Aximin. In case of overdosage, discontinue Aximin, treat symptomatically and institute supportive measures as required.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.